NCCC treats the first patients with new CAR T-cell therapy.
Dartmouth-Hitchcock Norris Cotton Cancer Center leads a new multi-center Phase I in-human clinical trial of anti-VISTA, a therapeutic antibody designed to target a molecule that keeps the immune system quiet against cancer.
A newly awarded $820,000 grant from The National Cancer Institute (NCI) will allow a team of investigators to increase clinical trial awareness and participation for rural patients.
NCCC researchers achieve conversion of a standard linear accelerator used for delivery of radiation therapy cancer treatment, to deliver a ‘FLASH’ ultra-high dose rate radiation therapy beam in standard patient geometry.
Multicenter study led by NCCC shows vastly improved turnaround time to get results from the lab to the oncologist using the newest technology in the cancer testing space.
Health system laying important groundwork to begin process of recovery for benefit of patients
Joanne Conroy, MD, Visits the Medical Intensive Care Unit at Dartmouth-Hitchcock Medical Center
Dartmouth researchers have created an AI model to classify colorectal polyps on histology slides. Evaluation using 238 slides from 24 institutions across 13 US states finds that the model performs as well as practicing pathologists.
A common anti-diabetes drug being tested in many clinical trials as an anti-cancer agent activated fat metabolism that promoted the survival of dormant breast cancer cells, suggesting that the drug has context-dependent effects on cancer cells.
Steven Leach, MD, Director of Dartmouth’s and Dartmouth-Hitchcock’s Norris Cotton Cancer Center (NCCC) shares the special precautions the clinicians and staff at NCCC have taken to help ensure the safety of patients during the COVID-19 crisis.